Clinical Trial · NCT05839483

CXCR4 Targeted PET Imaging in APA Preoperative Localization Diagnosis

Overview

The goal of this clinical trial is to evaluate the effectiveness of CXCR4 targeted PET imaging in preoperative localization diagnosis of primary aldosteronism (PA). Participants diagnosed with PA will be asked to be scanned by 68Ga-PentixaFor PET, and then underwent adrenal venous sampling (AVS). Then, the responsible adrenal adenoma will be resected by adrenalectomy, and examined with pathological section and staining. Researchers will compare the sensitivity and specificity between 68Ga-PentixaFor PET imaging and AVS in preoperative localization diagnosis of PA.

Sponsor

Zhongnan Hospital

Phase

N/A

Contacts

Zhe Meng (CONTACT)

mengzhe@whu.edu.cn

+86 15387041020

Zhe Meng (PRINCIPAL_INVESTIGATOR)

ClinicalTrials.gov

NCT05839483

Drug / Compound

Pentixafor

Isotope(s):

Target(s):

CXCR4

Ligand Class: Peptides

Chelator: DOTA

Eligibility

Inclusion

Patients with PA, confirmed by an elevated aldosterone/renin ratio (ARR) and an intravenous salt loading test.

Exclusion

Interfering treatment in between 68Ga-PentixaFor PET/CT and AVS.
Suspicion of adrenocortical carcinoma.
Estimated glomerular filtration rate \<40mL/min/1.73m2.
Suspicion of familial hyperaldosteronism type 1 (FH-1) or type 3 (FH-3).